{"title":"补充肌醇预防和治疗妊娠期糖尿病的疗效：一项荟萃分析。","authors":"Ru-Tong Wang, Ying-Qi Feng, Meng-Yao Wang, Yan-Hong Wei, Yu-Jun Huang, Yu-Jia Guo, Xuan Liu, Xiao-Can Lei, Kong-Wei Huang, Hua Huang","doi":"10.4239/wjd.v16.i9.107871","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gestational diabetes mellitus (GDM) poses a substantial health risk during pregnancy. However, the role of myo-inositol (MI) in GDM prevention and management remains controversial due to conflicting evidence and methodological limitations in previous studies.</p><p><strong>Aim: </strong>To assess the efficacy of MI in preventing and treating GDM, providing evidence-based guidance for clinical practice.</p><p><strong>Methods: </strong>A systematic review was conducted on studies published on the PubMed, Web of Science, and Embase databases from their inception date to July 2024. Twelve studies encompassing 9018 patients were included in the meta-analysis using fixed-effect and random-effects models. Heterogeneity was quantified with <i>I</i> <sup>2</sup> statistics and the Cochrane <i>Q</i> test, and study quality was appraised using the A Measurement Tool to Assess Systematic Reviews 2 checklist.</p><p><strong>Results: </strong>MI significantly reduced GDM incidence [relative risk (RR): 0.37; 95% confidence interval (CI): 0.32-0.42], fasting blood glucose [standard mean differences (SMD): -1.31 mg/dL; 95%CI: -1.83 to -0.79], and improved glucose tolerance test outcomes at 1-hour (SMD: -2.63 mg/dL; 95%CI: -3.87 to -1.40) and 2-hour (SMD: -0.95 mg/dL; 95%CI: -1.56 to -0.34). It also decreased the risk of preterm birth (RR: 0.37; 95%CI: 0.28-0.47) and pregnancy-induced hypertension (RR: 0.34; 95%CI: 0.25-0.47). A non-significant trend towards reduced cesarean section rates was observed (RR: 0.82; 95%CI: 0.71-0.94). MI reduced birth weight (SMD: -0.25 kg; 95%CI: -0.32 to -0.17), but had no effect on neonatal hypoglycemia (RR: 0.30; 95%CI: 0.08-1.21) or gestational age at birth (SMD: -0.13 weeks; 95%CI: -0.04 to 0.29).</p><p><strong>Conclusion: </strong>MI demonstrates therapeutic potential in GDM prevention and management, supporting its potential use as a preventive supplement in early pregnancy for high-risk women. Nonetheless, its therapeutic effects in women diagnosed with GDM require further validation.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 9","pages":"107871"},"PeriodicalIF":4.6000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444298/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy of inositol supplementation in the prevention and treatment of gestational diabetes mellitus: A meta-analysis.\",\"authors\":\"Ru-Tong Wang, Ying-Qi Feng, Meng-Yao Wang, Yan-Hong Wei, Yu-Jun Huang, Yu-Jia Guo, Xuan Liu, Xiao-Can Lei, Kong-Wei Huang, Hua Huang\",\"doi\":\"10.4239/wjd.v16.i9.107871\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Gestational diabetes mellitus (GDM) poses a substantial health risk during pregnancy. However, the role of myo-inositol (MI) in GDM prevention and management remains controversial due to conflicting evidence and methodological limitations in previous studies.</p><p><strong>Aim: </strong>To assess the efficacy of MI in preventing and treating GDM, providing evidence-based guidance for clinical practice.</p><p><strong>Methods: </strong>A systematic review was conducted on studies published on the PubMed, Web of Science, and Embase databases from their inception date to July 2024. Twelve studies encompassing 9018 patients were included in the meta-analysis using fixed-effect and random-effects models. Heterogeneity was quantified with <i>I</i> <sup>2</sup> statistics and the Cochrane <i>Q</i> test, and study quality was appraised using the A Measurement Tool to Assess Systematic Reviews 2 checklist.</p><p><strong>Results: </strong>MI significantly reduced GDM incidence [relative risk (RR): 0.37; 95% confidence interval (CI): 0.32-0.42], fasting blood glucose [standard mean differences (SMD): -1.31 mg/dL; 95%CI: -1.83 to -0.79], and improved glucose tolerance test outcomes at 1-hour (SMD: -2.63 mg/dL; 95%CI: -3.87 to -1.40) and 2-hour (SMD: -0.95 mg/dL; 95%CI: -1.56 to -0.34). It also decreased the risk of preterm birth (RR: 0.37; 95%CI: 0.28-0.47) and pregnancy-induced hypertension (RR: 0.34; 95%CI: 0.25-0.47). A non-significant trend towards reduced cesarean section rates was observed (RR: 0.82; 95%CI: 0.71-0.94). MI reduced birth weight (SMD: -0.25 kg; 95%CI: -0.32 to -0.17), but had no effect on neonatal hypoglycemia (RR: 0.30; 95%CI: 0.08-1.21) or gestational age at birth (SMD: -0.13 weeks; 95%CI: -0.04 to 0.29).</p><p><strong>Conclusion: </strong>MI demonstrates therapeutic potential in GDM prevention and management, supporting its potential use as a preventive supplement in early pregnancy for high-risk women. Nonetheless, its therapeutic effects in women diagnosed with GDM require further validation.</p>\",\"PeriodicalId\":48607,\"journal\":{\"name\":\"World Journal of Diabetes\",\"volume\":\"16 9\",\"pages\":\"107871\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444298/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4239/wjd.v16.i9.107871\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4239/wjd.v16.i9.107871","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Efficacy of inositol supplementation in the prevention and treatment of gestational diabetes mellitus: A meta-analysis.
Background: Gestational diabetes mellitus (GDM) poses a substantial health risk during pregnancy. However, the role of myo-inositol (MI) in GDM prevention and management remains controversial due to conflicting evidence and methodological limitations in previous studies.
Aim: To assess the efficacy of MI in preventing and treating GDM, providing evidence-based guidance for clinical practice.
Methods: A systematic review was conducted on studies published on the PubMed, Web of Science, and Embase databases from their inception date to July 2024. Twelve studies encompassing 9018 patients were included in the meta-analysis using fixed-effect and random-effects models. Heterogeneity was quantified with I2 statistics and the Cochrane Q test, and study quality was appraised using the A Measurement Tool to Assess Systematic Reviews 2 checklist.
Results: MI significantly reduced GDM incidence [relative risk (RR): 0.37; 95% confidence interval (CI): 0.32-0.42], fasting blood glucose [standard mean differences (SMD): -1.31 mg/dL; 95%CI: -1.83 to -0.79], and improved glucose tolerance test outcomes at 1-hour (SMD: -2.63 mg/dL; 95%CI: -3.87 to -1.40) and 2-hour (SMD: -0.95 mg/dL; 95%CI: -1.56 to -0.34). It also decreased the risk of preterm birth (RR: 0.37; 95%CI: 0.28-0.47) and pregnancy-induced hypertension (RR: 0.34; 95%CI: 0.25-0.47). A non-significant trend towards reduced cesarean section rates was observed (RR: 0.82; 95%CI: 0.71-0.94). MI reduced birth weight (SMD: -0.25 kg; 95%CI: -0.32 to -0.17), but had no effect on neonatal hypoglycemia (RR: 0.30; 95%CI: 0.08-1.21) or gestational age at birth (SMD: -0.13 weeks; 95%CI: -0.04 to 0.29).
Conclusion: MI demonstrates therapeutic potential in GDM prevention and management, supporting its potential use as a preventive supplement in early pregnancy for high-risk women. Nonetheless, its therapeutic effects in women diagnosed with GDM require further validation.
期刊介绍：
The WJD is a high-quality, peer reviewed, open-access journal. The primary task of WJD is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of diabetes. In order to promote productive academic communication, the peer review process for the WJD is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJD are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in diabetes. Scope: Diabetes Complications, Experimental Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes, Gestational, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Coma, Diabetic Ketoacidosis, Diabetic Nephropathies, Diabetic Neuropathies, Donohue Syndrome, Fetal Macrosomia, and Prediabetic State.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
